Business
AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
PRESS RELEASE AB SCIENCE PROVIDES INITIAL PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA Paris, 16 October 2025, 9pm CET AB Science SA (Euronext - FR0010557264 - AB) today provides an update on its AB8939 program in acute myeloid leukemia (AML). The webcast presentation is available on the company’s website, in the section « Press Releases »: https://www.ab-science.com/news-and-media/press-releases/ Highlights of the
About this update from Ab Science Sa
[{"type":"image","alt":"AB Science","displaySize":"","headline":null,"caption":"AB Science","className":"","disableSlideshowImg":false,"size":{"original":{"width":156,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AW2UM4sIueJ.X0XSJNjHhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2","width":156,"height":160}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"AB SCIENCE PROVIDES INITIAL PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA","length":153,"tagName":"p"},{"type":"text","content":"Paris, 16 October 2025, 9pm CET","length":31,"tagName":"p"},{"type":"text","content":"AB Science SA (Euronext - FR0010557264 - AB) today provides an update on its AB8939 program in acute myeloid leukemia (AML).","length":124,"tagName":"p"},{"type":"text","content":"The webcast presentation is available on the company’s website, in the section « Press Releases »: https://www.ab-science.com/news-and-media/press-releases/","length":171,"tagName":"p"},{"type":"text","content":"Highlights of the presentation are the following:","length":49,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In monotherapy, AB8939 has shown activity in MECOM, with long OS benefit","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"In combination therapy :","length":24,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"There is a strong rationale to combine AB8939 with Venetoclax, as the combination treatment is well-tolerated and both molecules have different and complementary targets in cancer cells","length":185,"tagName":"p"}]},{"val":[{"type":"text","content":"The disease control rate is 100% (3/3) and the partial response rate is 100% (3/3), including one patient in complete remission","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"These results were obtained after the first cycle of treatment (14 days of treatment) in patients receiving third- or fourth-line treatment, two of whom had previously progressed on venetoclax in combination with other chemotherapies","length":233,"tagName":"p...